Penny Stock Pick Report is pleased to alert investors of stocks on the move. Sign Up for our Stock Newsletter
Watson Pharmaceuticals, Inc. (NYSE: WPI) will be holding its second quarter earnings conference call on July 29 to discuss financial results. The call is scheduled for 8:30 a.m. ET and will release its financial results prior to the market open on the same day.
To access the call dial 877.251.7980 (domestic) or 706.643.1573 (international). A replay of the call will be made available approximately two hours following the conclusion of the call and can be accessed by dialing 800.642.1687 (domestic) or 706.645.921 (international) and entering passcode: 18892418
A live webcast of the earnings conference call will also be available on the Watson Investor Relations Web site at http://ir.watson.com with a replay of the webcast to be made available as well.
Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of brand pharmaceuticals focused on Urology, Women's Health and Nephrology/Medical.
About Us
Sign Up for Penny Stock Pick Report’s Free Small Cap Newsletter. To subscribe please enter your email address in the frame at the bottom of this page or visit us at our website.
Subscribe at the bottom of this page.
About Us
Penny Stock Pick Report is a leading stock web site that provides free stock alerts on stocks that are poised to make big gains. We also track small cap companies that could be on the brink of a massive breakout. To feature a company on our web site please contact us at the email listed below.
Penny Stock Pick Report is an independent electronic publication that provides information on selected publicly traded companies. This publication is not a registered investment advisor or broker-dealer. Our affiliates, officers, directors and employees may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above. View our full disclaimer.
